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We have created a transgenic mouse with a hypomorphic allele of the vesicular monoamine transporter 2
(Vmat2) gene by gene targeting. These mice (KA1) have profound changes in monoamine metabolism and
function and survive into adulthood. Specifically, these animals express very low levels of VMAT2, an endog-
enous protein which sequesters monoamines intracellularly into vesicles, a process that, in addition to being
important in normal transmission, may also act to keep intracellular levels of the monoamine neurotrans-
mitters below potentially toxic thresholds. Homozygous mice show large reductions in brain tissue mono-
amines, motor impairments, enhanced sensitivity to dopamine agonism, and changes in the chemical neuro-
anatomy of the striatum that are consistent with alterations in the balance of the striatonigral (direct) and
striatopallidal (indirect) pathways. The VMAT2-deficient KA1 mice are also more vulnerable to the neurotoxic
effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in terms of nigral dopamine cell death. We suggest that
the mice may be of value in examining, long term, the insidious damaging consequences of abnormal intra-
cellular handling of monoamines. On the basis of our current findings, the mice are likely to prove of
immediate interest to aspects of the symptomatology of parkinsonism. They may also, however, be of use in
probing other aspects of monoaminergic function and dysfunction in the brain, the latter making important
contributions to the pathogenesis of schizophrenia and addiction.
There are three major monoaminergic cell groups, ramifying
extensively throughout the brain and distinguished by their
neurotransmitter phenotype: noradrenaline (norepinephrine),
dopamine, and serotonin (3, 5, 25). The neural specific vesic-
ular monoamine transporter 2 (VMAT2) packages these
monoamine neurotransmitters into vesicles after they have
been synthesized from their amino acid precursors, tyrosine
and tryptophan, in the nerve terminal. This sequestering action
is important for normal neurotransmission and may also act to
keep intracellular levels of the monoamine transmitters below
potentially toxic levels (7, 19). The diffuse monoamine systems
modulate a wide range of brain functions, spanning sensory-
motor, motivational, and cognitive domains. Abnormalities in
the functioning of these systems have been suggested to play
key roles in the etiology of a number of disorders, including
Parkinson’s disease (4), schizophrenia (6, 32), and addiction
(16, 26).
We have created a transgenic mouse by utilizing a targeted
insertion in which endogenous VMAT2 is no longer expressed
at levels detectable by in situ hybridization and immunohisto-
chemistry methods and in which there are major changes in
monoamine metabolism. Unlike other reported knockouts of
the Vmat2 gene (9, 34, 36), these mice survive into adulthood
as homozygotes and do not suffer gross physical defects, offer-
ing a unique opportunity to examine more subtle aspects of the
behavioral and brain phenotypes resulting from abnormal in-
tracellular handling of monoamine transmitters. Here we re-
port on the creation of the mouse and provide data at the
behavioral, neurochemical, and molecular levels which reca-
pitulate some of the symptomatology of Parkinson’s disease
and which may therefore provide insight into possible neuro-
pathological mechanisms contributing to this neurodegenerat-
ing condition.
MATERIALS AND METHODS
Targeting vector construction. The mouse VMAT2 locus was cloned from a
partial MboI 129/Sv genomic library. Genomic SacI and HindIII subclones were
generated in pBluescript (Stratagene). The b-actin neo cassette (kindly supplied
by Austin Smith, Centre for Genome Research, Edinburgh, United Kingdom)
was cloned into the BamHI site of a 2.5-kb HindIII-BamHI fragment containing
the Vmat2 promoter and the leader exon in pBluescript (Stratagene). A 2.2-kb
PvuII fragment from the third intron of the Vmat2 gene was cloned into the
blunt-ended NotI site of this construct. The herpes simplex virus thymidine
kinase gene (21) used for negative selection was cloned into the BgIII site at the
39 end of the construct. The structure of the targeting vector is shown in Fig. 1A.
Gene targeting in ES cells. The targeting vector (30 mg) was linearized with
SalI and introduced into 129/Ola CGR 8.8 embryonic stem (ES) cells (1 3 107
cells; kindly supplied by William Scarnes, Centre for Genome Research) by
electroporation. Transfected cells were seeded onto Neor STO feeder cells, and
double selection (150 mg of G418/ml, 2 mM ganciclovir) was started 24 h after
electroporation. A total of 325 double-drug-resistant colonies were picked 8 to 11
days after electroporation and screened for homologous recombination by
Southern blot analysis. Six clones were identified as being correctly targeted with
the 39 external probe. Using a 59 external probe, we found that in five out of those
six clones homologous recombination resulted in the deletion of exons 1 and 2
(see Fig. 3B), resulting in a Vmat2 null allele. Homozygous mice derived from
one of these cell lines (GB1/1) died shortly after birth. In the KA1 cell line, one
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FIG. 1. Targeted insertion into the third intron of the Vmat2 gene. (A) The Vmat2 gene in the 129 wild-type mouse genome and mutant
sequences after targeted insertion of the vector, with prominent restriction endonuclease sites shown (B, BamHI; H, HindIII; K, KpnI; S, SacI; X,
XbaI; and Xh, XhoI). Neomycin resistance sequences (neo) and sequences recognized by the Vmat2 39 and 59 hybridization probes are indicated.
Homologous sequences in the mouse genome and of the targeting vector and the neomycin resistance (neo) and the herpes simplex virus thymidine
kinase (HSV tk) sequences are indicated. (B) Southern blot analysis of hybridization of radiolabeled Vmat2 59 and 39 hybridization probes with
genomic DNA extracted from the tail tips of wild-type (lane 1), heterozygous (lane 3), and homozygous (lanes 2 and 4) mice digested with the
restriction endonucleases HindIII and XbaI (H1X), BamHI (B), KpnI (K), or Xhol (Xh). (C) Sequence of the PCR product generated with a
forward primer specific for the 59 flanking genomic sequences (SF1) and a reverse primer specific for the 59 end of the transgene (SR1) (see also
PCR primer in panel A). (D) Vmat2 RNA expression in the major monoaminergic cell body groups in the brain of homozygous KA1 mice. In situ
hybridization was carried out using end-labeled radioactive oligonucleotides complementary to the first and second exon of the Vmat2 gene (see
also panel A). The representative dark-field photomicrographs show the expression of Vmat2 mRNA in the substantia nigra (SN) and ventral
tegmental (VTA), the dorsal raphe nucleus (RAPHE), and in the locus coruleus (LC) in a wild-type mouse. No signal was detected in the
homozygous KA1 mutant.
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arm of the construct did not recombine as predicted but inserted into the Vmat2
locus (Fig. 1A). The insertion site was confirmed by Southern blot analysis by
using 39 and 59 hybridization probes (Fig. 1B) and verified by PCR analysis of the
junction between the transgene and the genome (Fig. 1C).
Generation of chimeric KA1 and GB1/1 mice. Chimeric mice were generated
by injection of the selected ES cells into blastocysts of C57BL/6 mice using
standard techniques (29). Highly chimeric males were bred with C57BL/6 fe-
males, and agouti offspring were tested for germ line transmission by Southern
blot analysis of DNA extracted from tail-tip specimens. Homozygous mice were
obtained by interbreeding heterozygotes. In all subsequent experiments, the
genotype of the mice was confirmed by Southern blot analysis of tail tips.
In situ hybridization histochemistry. Brains from adult mice were removed,
rapidly frozen, and stored at 270°C. Ten-micrometer sections were cut (cryostat)
and processed for in situ hybridization by using a mix of four different 35S-labeled
oligonucleotide probes directed against mouse Vmat2 mRNA: 59-GCAGCAGC
ACCAGATCGCTCAGGGCCAT-39 (exon 1, nucleotides 1 to 24); 59-GGATC
AGCTTGCGCGAGTGGCGGCTGTCCCGCAGCC-39 (exon 1, nucleotides 28
to 63); 59-GCCTTGGGTGACTCCCCTCCTGGGAGGCCCCCCCGT GGC-39
(exon 2, nucleotides 272 to 310); and 59-CATTTATGCAGAATCCAGCAAAC
ATGG GAATTGGATAGCC-39 (exon 2, nucleotides 179 to 218) (33). En-
kephalin mRNA was detected with 35S-labeled antisense oligonucleotide probes
for mouse proenkephalin cDNA (nucleotides 2428 to 2463; GenBank accession
number U09941), and substance P mRNA was detected with 35S-labeled oligo-
nucleotide probes antisense to mouse beta-preprotachykinin A cDNA (nucleo-
tides 234 to 270; GenBank accession number D1007723). Hybridization was
carried out in 23 SSC (13 SSC is 0.15 M NaCl plus 0.015 M Sodium citrate),
50% deionized formamide, 10% dextran sulphate, 250 mg sonicated salmon
testes DNA/ml, 13 Denhardt’s solution, and 3% b-mercaptoethanol with a
probe concentration of 100,000 dpm/ml at 37°C in a humidified chamber. The
sections were washed three times with 13 SSC at 55°C for 30 min and with 13
SSC at room temperature (RT) for 1 h. Dehydrated sections were exposed to
Kodak b-Max autoradiography film at RT for 4 to 21 days. After development of
the film, the sections were coated with nuclear track emulsion (Ilford K2) in the
dark and stored at 4°C in the dark. Quantification of the hybridization signal was
carried out by counting silver grains on individual cells with the SeeScan micro-
autoradiography system (Cambridge, United Kingdom).
Immunohistochemical analysis. Brains from adult mice were removed, fixed in
4% paraformaldehyde (PFA) for at least 12 h at 4°C, and then kept in 30%
sucrose in phosphate-buffered saline (PBS). Fifty-micrometer sections were cut
and processed for immunohistochemistry using a 1:1000 dilution of an affinity-
purified rabbit polyclonal antiserum with antibodies raised against a synthetic
peptide from the intracellular C-terminal region of the human VMAT2 gene
(Chemicon). VMAT2 immunoreactivity visualized by this VMAT2 antiserum was
detected in all the major monoaminergic cell groups in the brain, as expected
(28). Tyrosine hydroxylase (TH) immunoreactivity was visualized using a mono-
clonal anti-TH antibody purchased from Sigma (mouse ascites fluid clone TH-2).
Preliminary quantification of TH-immunopositive cells in the substantia nigra
and ventral tegmental areas were made using unbiased dissector methods with an
Olympus optical dissector-stereology package.
RT-PCR analysis. Total midbrain RNA from homozygous and wild-type
GB1/1 and KA1 neonates was isolated using a Qiagen RNA purification kit and
reverse transcribed with Superscript II reverse transcriptase (RT) and random
primer oligonucleotides (mostly hexamers) (Gibco BRL) under recommended
conditions. Of the first strand reaction mixture, 10% was used for PCR with Taq
DNA polymerase (Qiagen). The primers used for the PCR amplification of the
first strand reaction were designed according to the mouse Vmat2 cDNA se-
quence in the second exon (59-GCTACCTGTACAGCATTAAGCACG-39) for
the forward primer and in exon 12 for the reverse primer (59-CCAACTCCAA
AGTTGGGAGCG-39) (33), and according to the mouse Hprt cDNA sequence
at nucleotide position 346 (59-CCTGCTGGATTACATTAAAGCACTG-39) for
the forward primer and at nucleotide position 714 (59-GTCAAGGGCATATC
CAACAACAAAC-39) for the reverse primer (22). RT-PCR amplification con-
ditions were denaturing for 2 min at 94°C followed by 36 cycles of 1 min at 94°C,
1 min at 60°C, and 1 min at 72°C.
Western blot analysis. Membrane proteins were prepared from the striatum of
wild-type and KA1 homozygous mutant mice. The tissue was homogenized using
a Waring blender in 10 volumes of homogenizing buffer (50 mM HEPES, 1 mM
disodium EDTA, 1 mM EGTA) containing 1 mM phenylmethylsulfonyl fluoride
and 1 mM pepstatin and centrifuged at 1,000 3 g and the pellet was discarded.
The membrane fraction was retrieved by centrifugation at 40,000 3 g, washed
twice in the homogenization buffer, and finally resuspended in the same buffer to
a concentration of 20 mg/ml and stored at 280°C. The protein content was
determined using the Bio-Rad Bradford reagent protocol. A total of 30 mg of
protein of each membrane vesicle preparation was separated by electrophoresis
through polyacrylamide and transferred to nitrocellulose by electroblotting. The
blot was incubated with a crude rabbit antiserum with antibodies raised against
a peptide present in the human VMAT2 gene at a 1:1000 dilution. As a control
for the amount of loaded protein, an identical gel was run in parallel and stained
with Coomassie blue (data not shown).
Quantification of brain monoamines. Dissected brain regions were sonicated
in 0.1 M perchloric acid and 0.1 mM EDTA (10 mg/100 ml). The extracts were
then centrifuged for 15 min and the supernatant was collected and stored at
220°C. Monoamines (noradrenaline, dopamine, serotonin) and metabolites (di-
hydroxyphenylacetic acid [DOPAC], homovanillic acid [HVA], and 5-hydroxy-
indolacetic acid [5-HIAA]) were measured with high-pressure liquid chromatog-
raphy (HPLC) using electrochemical detection as described previously (12).
Behavioral testing. All mice were weaned at 21 days of age and housed with
two to five same-sex littermates. Male mice were used in the behavioral testing.
All animals were maintained on a 12-h light-dark cycle (lights on at 0700 to 1900)
and were permitted free access to food and water. Beam walking was assessed
using 1-m-long wooden beams suspended 80 cm from the floor. The mice were
placed on one end of the beam, and the time taken to reach the other end (where
the mice entered a cardboard shelter) was assessed. The number of slips and falls
in negotiating the beams were also recorded. Task difficulty was increased by
altering the diameter and shape of the beams (from least to most difficult):
15-mm round, 10-mm square, and 10-mm round beams. In order to ensure the
animals were fully habituated to the test situation, training took place over 4
days, with the more difficult beams being gradually introduced. On day 4 (test
day), the mice were given six attempts on each of the beams. The data presented
are the mean of the six attempts. Novelty place preference was assessed in an
apparatus with two 29 by 29 by 29-cm compartments, each separated by a small
central compartment. Each main compartment was distinguished by color (black
or white) and flooring (sandpaper or smooth). During the test, the mouse was
placed in one or the other compartment for 60 min, making it familiar relative to
the other unexplored and therefore novel side. Then the mice were given a free
choice between both compartments for 10 min, and the time spent in the novel
side, the number of visits made, and the number of exploratory rears when in the
novel side were measured. Stereotyped behaviors following the intraperitoneal
(i.p.) injection of d-amphetamine sulphate (3 mg of free base/kg of body weight)
were assessed blind from videotapes by using a scoring system based on that used
by Mittleman et al. (23). Behavior was monitored for 1 h postinjection in spe-
cially adapted Perspex boxes.
FIG. 1—Continued.
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MPTP treatment. For this experiment, only male mice backcrossed into
C57BL/6 for five generations were used. Three doses of 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) (Sigma M-0896) were administered i.p. 16
mg/kg, 3 h apart. Two control mice in each group received three i.p. injections of
saline. Mice were kept on heated blankets for 24 h after the injections and culled
8 days after drug treatment. All mice were perfused with PBS and 4% PFA. The
brains were removed, fixed in 4% PFA for 12 h at 4°C, and then stored in 30%
sucrose in PBS. Fifty-micrometer sections were cut and processed for immuno-
histochemistry using a 1:1000 dilution of a TH antibody (Sigma T-1299). Sections
were dried and mounted in Depex. Cell counting was performed using a com-
puter-assisted stereological toolbox (CAST-Grid; Olympus). All cell counts were
done blind to genotypes and drug treatments and performed at 100-fold magni-
fication.
RESULTS
Generation of KA1 and GB1/1 transgenic mice. To generate
VMAT2-deficient mice, we used a replacement vector contain-
ing sequences homologous to the Vmat2 target sequences with
a neomycin resistance (neo) expression cassette inserted within
the region of homology (Fig. 1A). The expected double-recip-
rocal recombination resulted in deletion of exons 1 and 2 and
flanking intron sequences and a replacement of the deleted
region with the neo cassette (see Fig. 3B). Homozygous mice
derived from these clones (GB1/1 mice) died, as has been
previously reported with Vmat2 knockouts soon after birth (9,
34, 36). However, we also identified a clone (KA1) that carried
a hypomorphic Vmat2 allele, in which a single recombination
occurred on one arm of the construct and resulted, as detailed
in Fig. 1A, in an insertion of the neo cassette and of the leader
exon with 59 flanking sequences of the construct into the third
intron of the Vmat2 gene. Probes for 59 and 39 flanking se-
quences of the insertion detected polymorphic restriction frag-
ments of the expected sizes in transgenic tail DNA with all
enzymes tested (Fig. 1B). Insertion of exogenous DNA is
known to result in deletions of neighboring sequences of the
endogenous DNA. To examine this possibility in the KA1
mice, primers were designed to use PCR to analyze the junc-
tion between the transgene and 59 flanking sequence. The
sequence of the PCR product is given in Fig. 1C. The sequence
comparison of the PCR product with the cloned genomic re-
gion revealed the location of the insertion as well as a deletion
of 245 bp from the 59 end of the transgene. The other arm of
the targeting construct and sequences 39 from the insertion
event stayed intact after homologous recombination. Using the
39 probe, no differences in the hybridization patterns between
the knockout line GB1/1 and KA1 could be found with any
enzymes tested (data not shown), indicating that the single
recombination event did not cause any major deletions and/or
rearrangements in the endogenous Vmat2 gene. Mice derived
from clone KA1 were able to survive with the mutation on both
alleles (homozygotes) and were used in the present studies at
between 3 and 6 months of age.
VMAT2 expression in KA1 mice. The insertion of the trans-
gene construct in the KA1 mice was effective in blocking Vmat2
expression, as confirmed by Northern blotting (data not
shown), in situ hybridization, and immunohistochemical evi-
dence from brain sections (Fig. 1D and 2). In situ hybridization
of brain sections with oligonucleotides complementary to the
Vmat2 message indicated an absence of Vmat2 mRNA in the
major monoaminergic cell body groups in the brain of homozy-
gous KA1 mice (Fig. 1D); this was confirmed by immunocyto-
chemistry by using a VMAT2 antibody to show that no
VMAT2 protein was detectable in the midbrain and striatal
regions of the brain in the mutant mice, although it was readily
detectable in wild-type littermates (Fig. 2). However, the pres-
ence of the monoamine cells in the substantia nigra and their
processes in the striatum in homozygous KA1 mice could be
readily visualized with an anti-TH antibody. Furthermore, no
reduction in the number of TH-positive cells could be detected
using an unbiased counting method, performed by using the
computer-assisted stereological toolbox (CAST-Grid) system
from Olympus. TH-immunopositive cells were counted from
30 serial sections (50 mm) in the A8, A9, and A10 regions from
five animals homozygous for the KA1 insertion and four wild-
type mice. Total cell counts (mean 6 standard error of the
mean [SEM]) were 15,980 6 1,305 for the wild-type (n 5 4)
and 16,328 6 1,102 for the homozygous animals (n 5 5). There
was no significant difference in the number of cells between the
two groups (Student’s t test). PCR amplification of cDNA
made from homozygous KA1 and GB1/1 brain RNA with
Vmat2-specific primers detected normal transcripts in homozy-
gous KA1 neonates but not in homozygous GB1/1 neonates
(Fig. 3A). Sequence analysis of the KA1 PCR amplification
product confirmed that an intact correctly spliced message can
be generated from the KA1 allele. This result indicates that
VMAT2 may be expressed, but at very low levels. Although no
residual VMAT2 protein could be detected using a polyclonal
VMAT2 antibody in immunohistochemical analyses, residual
amounts of VMAT2 protein could be detected with Western
blots of purified vesicle membrane proteins from the striatum
of homozygous KA1 mice (Fig. 3C). Enhanced chemilumines-
cence Western blotting analysis detected background bands of
higher molecular weight in both samples, whereas the smaller
(’55 kDa) VMAT2-specific band, which was readily detect-
able in the wild-type mouse, was barely detectable in the ho-
mozygous KA1 mutant.
Monoamine brain chemistry in VMAT2-deficient KA1 mice.
The loss of VMAT2 expression in the viable KA1 mice was
associated with large reductions in the brain concentrations of
the monoamine transmitters. Figure 4 illustrates the pattern of
neurochemical changes seen in selected brain areas. There
were general reductions in tissue levels of dopamine, nor-
adrenaline, and serotonin, which in most brain regions were
dependent on gene dosage. Whilst there were also reductions
in the main metabolites, HVA, DOPAC, and 5-HIAA, it was
noticeable that the ratio of metabolites to transmitter was in
many cases increased, suggesting an increased turnover of
monoamines in homozygous mice. Quantitative analysis of TH
immunohistochemistry (Fig. 2) indicated that, at the age tested
(3 to 6 months), the reduced levels of dopamine in terminal
and cell body regions of the VMAT2-deficient mice occurred
in the absence of any significant loss of dopamine cell bodies in
the substantia nigra and ventral tegmental area, suggesting that
it was, in the main, the abnormal handling of dopamine by the
vesicles that was responsible for the reductions in transmitter
content.
Motor functioning in VMAT2-deficient KA1 mice. Basic vi-
sual inspection of the VMAT2-deficient mice indicated no
obvious physical abnormalities compared to wild-type controls,
though they did weigh less at the time of testing (wild type,
35.1 6 1.32 g; heterozygous, 33.15 6 1.72 g; homozygous,
29.24 6 1.14 g). However, motor deficits became apparent in a
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beam walking task, a sensitive test of motor coordination and
balance, whereby VMAT2-deficient KA1 mice took longer and
made more slips in crossing narrow wooden beams suspended
80 cm from the floor (Fig. 5A). The effects on motor perfor-
mance were probably largely independent of motivational fac-
tors, since the beam walking training protocol allowed for
substantial habituation to the test situation with gradually in-
creasing levels of difficulty. Moreover, the VMAT2-deficient
KA1 mice showed normal reactivity in a novelty place prefer-
ence task, as indexed by the time spent in the novel as opposed
to the familiar environment (Fig. 5A). This was despite evi-
dence of a general reduction in locomotor activity in the task,
as indexed by crossings and rears within the test apparatus
(Fig. 5A). Novelty place preference was assessed in an appa-
ratus with two 29 by 29 by 29-cm compartments distinguished
by color (black and white) and sandpaper flooring on one side.
After 60 min of habituation in one of the compartments, an
opening was made available for access to the other compart-
ment. Time spent in the novel chamber as well as the number
of visits into the novel environment and the number of rears in
the novel place were recorded for 10 min. There were no
significant group differences in the time spent on the novel side
of the test apparatus. There were, however, significant group
differences between homozygous, heterozygous, and wild-type
mice in the number of visits and rears in the novel environ-
ment. The ability of the VMAT2-deficient mice to make the
distinction between a novel and a familiar environment also
argued against confounds in the interpretation of motor effects
arising from underlying sensory deficits.
Enhanced amphetamine-induced stereotypy in VMAT2-de-
ficient KA1 mice concurrent with altered chemical neuroanat-
omy in the striatum. The VMAT2-deficient KA1 mice also
FIG. 2. VMAT2 and TH immunoreactivity in striatal and midbrain regions of KA1 homozygous mice. (A) Striatal sections from wild-type and
homozygous KA1 mice were stained for VMAT2 immunoreactivity (VMAT2) using a specific antiserum. VMAT2 immunoreactivity is present in
the caudate putamen (CPu) and the nucleus accumbens (Nacc) of wild-type mice but absent in those structures in homozygous mice. In striatal
sections from wild-type and homozygous KA1 mice stained for TH immunoreactivity using a specific antiserum, the level of TH immunoreactivity
in the caudate putamen and the nucleus accumbens was similar in both wild-type and homozygous mice. (B) VMAT2 immunostaining is absent
in the substantia nigra (SN) and the ventral tegmental area (VTA) of the homozygous KA1 mouse and present in the wild-type mouse, whereas
TH immunoreactivity is also present in the dopamine cell body region of homozygous mice. The apparent lack of differences in TH immunore-
activity between wild-type and homozygous mice, seen on gross visual inspection, was confirmed by quantitative analysis of four wild-type and five
homozygous animals.
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showed enhanced stereotypic behaviors in response to the do-
pamine releasing drug d-amphetamine (Fig. 5B). Homozygous
KA1 mice showed a dramatically increased responsiveness to a
single d-amphetamine injection (3 mg/kg) given i.p., resulting
in increased stereotyped behaviors of these mice compared to
their wild-type and heterozygous littermates. No group differ-
ences were detected in response to saline injections, indicating
that these effects were unlikely to be due to preexisting differ-
ential reactivities to the i.p. injections per se (data not shown).
Dopamine effects in dorsal striatum are a key substrate for
behavioral stereotypies (30), so we examined molecular neu-
roanatomical indices of dopamine function in this structure for
possible correlates of the altered sensitivity to amphetamine.
Whilst there were no differences in gene expression of dopa-
mine receptors of the D1 and D2 subtypes (data not shown),
there was evidence, as illustrated in Fig. 5C, of changes in
mRNA levels of substance P and enkephalin, peptides which
distinguish between the two main output pathways from the
striatum, the striatonigral (direct) and striatopallidal (indirect)
pathways (11). As illustrated with in situ hybridization in Fig.
5C, homozygous VMAT2-deficient mice showed a striking
down-regulation of substance P mRNA and an up-regulation
of enkephalin mRNA in the striatum, giving rise, in turn, to the
possibility of abnormalities in the organization of dopamine-
mediated signaling via direct and indirect efferents.
Increased toxin sensitivity in midbrain of KA1 homozygous
mice. We noted that in several ways the VMAT2-deficient
KA1 mice modeled aspects of the symptomatology of Parkin-
son’s disease, namely in terms of a lowered brain content of
monoamines, especially dopamine (14), the presence of motor
deficits (27), and the pattern of changes in peptides associated
with the direct (substance P) and indirect (enkephalin) output
FIG. 3. RT-PCR and Western blot analysis of homozygous KA1 insertional mutants and homozygous GB1/1 knockout mice. (A) Ethidium-
stained agarose electrophoresis of RT-PCR products. Total midbrain RNA from homozygous (hom) and wild-type (wt) GB1/1 and KA1 neonates
was isolated and reverse transcribed. Expression of Vmat2 mRNA was detected using specific primers for exon 2 and exon 12 of the mouse Vmat2
gene (33). These primers amplified Vmat2 cDNA made from homozygous KA1 mice, but no amplification product was generated with cDNA made
from homozygous GB1/1 neonates. The quality of all cDNA preparations was examined by performing control RT-PCRs with primers to
hypoxanthine phosphoribosyltransferase (Hprt) (22). (B) Schematic representation of the genomic organization of the Vmat2 wild-type allele, the
KA1 insertion allele, and the GB1/1 knockout allele. The wild-type allele is transcriptionally active. The KA1 insertion interferes severely with
transcription, and only a small amount of Vmat2 message is generated. In the GB1/1 knockout line, the first and second exon of the Vmat2 gene
are deleted, completely abolishing the generation of normal Vmat2 message. (C) Western blot of striatal membrane preparations from homozygous
and wild-type KA1 mice probed with a polyclonal antibody against the VMAT2 protein. Both lanes contain comparable amounts of protein, as
determined by the Bradford method. Quantitative analysis of the blot using SeeScan indicated a decrease in signal of more than 95% in
homozygotes below that of the wild-type signal. The position of the VMAT2-specific band is indicated by the arrowhead. The higher molecular
weight band is nonspecific, being found in extracts from controls and mutants.
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FIG. 5. Motor functioning and dopamine supersensitivity in KA1 mice. (A) Homozygous (light gray bars) and heterozygous (dark gray bars)
KA1 mice could not perform as well as their wild-type (black bars) littermates in a beam walking task, but they showed a normal preference for
a novel environment. The results, for each beam diameter and shape, are the mean latencies to cross the beam 6 SEM of six crossings done by
15 males of each genotype in the fourth (i.e., the final) test session. Data were analyzed by the Tukey-Kramer multiple comparison test, which
indicated significant group differences at each level of difficulty (p, P , 0.05; pp, P , 0.001, compared with the wild-type group [Student t test]).
The novelty place preference, assessed using the Tukey-Kramer multiple comparisons test, did not show any significant group differences in the
time spent on the novel site. There were, however, significant group differences in the number of visits and rears in the novel environment. The
results are represented as mean 6 SEM for 15 mice of each genotype. p, P , 0.05; pp, P , 0.001, compared with the wild-type group (Student
t test). (B) Increased responsiveness to systemically administered d-amphetamine (3 mg/kg) given i.p., on stereotyped behaviors in wild-type,
heterozygous, and homozygous animals. Stereotypy ratings, based on the scoring system of Mittleman et al. (23), were taken blind for 1 h
postinjection. The lower the rating, the lower the observed rate of stereotypy, and vice versa. The results are the mean scores 6 SEM, registered
in 12 5-min bins, for 11 wild-type, 8 heterozygous, and 9 homozygous mice. Analysis of variance indicated a significant main effect of group (P ,
0.01), consistent with an increased response to d-amphetamine in the homozygous mice. (C) An altered chemical neuroanatomy in the striatum
of male VMAT2-deficient KA1 mice expressing substance P and enkephalin mRNA is shown in striatal sections from wild-type mice and
homozygous KA1 mutants, hybridized with oligonucleotides complementary to the substance P and enkephalin messages. The relative down-
regulation of substance P mRNA expression and the relative up-regulation of enkephalin mRNA expression in the striatum of KA1 homozygous
mice was quantified by silver grain counting on mRNA-positive cells. The difference between the two groups was compared by the Student t test
and showed a significant difference in the number of silver grains per square millimeter of cell area between wild-type and homozygous mice for
both substance P (P , 0.001) and enkephalin (P , 0.05).
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pathways of the striatum (8, 17). However, the mice did not
exhibit overt dopamine cell loss in midbrain areas (Fig. 2), the
classical finding in Parkinson’s disease (4). We were interested
to see, therefore, whether the mice have a lowered threshold
for dopamine cell damage caused by using the neurotoxin
MPTP (15). As shown in Fig. 6, this was found to be the case,
as significantly more dopamine cell loss occurred in the sub-
stantia nigra and the ventral tegmental area of the VMAT2-
deficient mice following toxin administration compared to re-
sponses in their heterozygous and wild-type littermates. We
are currently examining the possibility that a similar underlying
vulnerability to damaging events may be manifest with increas-
ing age of the mice. Such findings would be consistent with the
usual history of idiopathic Parkinson’s disease, in which age is
a major risk factor (31), and may also bear on recent specula-
tion about VMAT2 and its role in mediating efficient clearance
of dopamine in the selective vulnerability of midbrain dopa-
mine neurons in the disease (18, 35).
DISCUSSION
We describe here the development of a mouse line which,
according to analyses by in situ hybridization and immunohis-
tochemical methods, does not express detectable levels of
VMAT2 and which, in contrast to other reported knockouts of
the Vmat2 gene (9, 34, 36), survives as homozygotes into adult-
hood without gross physical deficits. The reason why the mice
survive is related to the nature of the recombination event and
the observation that the suppression of gene expression is not
complete. KA1 homozygous mice survive because the insertion
event in this line differs from that in the GB1/1 line in permit-
ting residual expression of Vmat2, which was low enough to
escape detection by Northern blotting, in situ hybridization,
and immunohistochemical methods but which was sufficient to
rescue the mouse. Consistent with this explanation, a more
sensitive RT-PCR method did reveal low levels of endogenous
Vmat2 message in the KA1 line that was absent in the GB1/1
line (Fig. 3A). Also, extremely low levels of protein could be
detected in Western blots in striatal membrane proteins iso-
lated from homozygous KA1 mice (Fig. 3C). A precedent for
this rescue has recently been reported where an insertion into
intron 20 of the N-methyl-D-aspartate receptor subunit NR1
resulted in mice with only 5% of normal expression levels.
These mice have been used to study schizophrenia-like behav-
ioral abnormalities (24), whereas the NR1 knockout mice die
perinatally (10). That this small amount of protein may be
functionally active in the KA1 mice was confirmed by fast cyclic
FIG. 6. MPTP treatment of wild-type, heterozygous, and homozygous KA1 mice. (A) TH-immunopositive cells in sections from the substantia
nigra pars compacta of saline-treated and MPTP-treated wild-type, heterozygous, and homozygous KA1 mice. (B) Number of TH-immunopositive
cells in the substantia nigra pars compacta of saline-treated and MPTP-treated wild-type, heterozygous, and homozygous KA1 mice. TH-
immunopositive cells were counted from 30 serial sections from 4 wild-type, 3 heterozygous, and 3 homozygous MPTP-treated and 4 saline-treated
(2 homozygous and 2 wild-type) mice. The cell loss was significantly increased in MPTP-treated heterozygous and homozygous KA1 mice
compared to the MPTP-treated wild-type littermates. The difference between the three groups was compared by the Student t test and showed a
significant difference in the number of TH-positive cells between wild-type and heterozygous MPTP-treated mice (P , 0.01) and between wild-type
and homozygous MPTP-treated mice (P 5 0.001).
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voltammetry on coronal striatal slices prepared from homozy-
gous KA1 mutants and wild-type littermates, where small
amounts of vesicular dopamine released in homozygotes could
be measured (J. A. Stamford and J. Patel, personal communi-
cation). Whilst the residual expression of VMAT2 in the KA1
line rescued the lethal phenotype, the mice were not normal.
The survival of the VMAT2-deficient KA1 mice allowed us
to examine the effects of abnormalities in the main intracellu-
lar uptake mechanism for handling monoamine neurotrans-
mitters in the adult, homozygous animal. A major brain phe-
notype was a profound reduction in the levels of monoamine
transmitters. In the case of dopamine, we ascertained that
these neurochemical changes occurred in the absence of any
overt loss of dopamine cell bodies, suggesting that it was, in the
main, the abnormal handling of dopamine by the vesicles that
was responsible for the reductions in transmitter content. The
changes in brain monoamine metabolism were accompanied
by motor deficits and an enhanced behavioral responsiveness
to d-amphetamine, manifest as increased stereotypy. The in-
creased sensitivity to d-amphetamine did not appear to be
related to changes in striatal dopamine receptors of the D1 or
D2 type (data not shown). However, we did observe large
effects on substance P and enkephalin gene expression in
VMAT2-deficient KA1 mice, which may be indicative of an
altered functional architecture in the striatum. In our mouse
model, small amounts of vesicular and nonvesicular dopamine
released in response to d-amphetamine might act on “super-
sensitive” dopamine receptors of the direct and/or indirect
striatal efferents, giving rise to an overall enhanced effect of
dopamine agonism, which is expressed as behavioral stereo-
typy. The enhanced sensitivity of the KA1 mice to d-amphet-
amine may also have been related to changes in presynaptic
function, such as increased dopamine transport into or out of
the cell, which can be measured but which we did not attempt
to measure in the present work. The KA1 mouse models in
several ways aspects of the symptomatology of Parkinson’s
disease, namely, in terms of a lowered brain content of mono-
amines, especially dopamine (14), the presence of motor def-
icits (27), and the pattern of changes in peptides associated
with the direct (substance P) and indirect (enkephalin) output
pathways of the striatum (8). Together with electrophysiolog-
ical data (1), effects on the chemical neuroanatomy of the
striatum form a major part of the evidence indicating a key role
for perturbations in the balance of the direct and indirect
pathway functioning in the motor abnormalities present in
Parkinson’s disease (17), a theoretical standpoint which pro-
vides the basis for the recent surgical approaches to treating
the condition (2) and may also provide some insight into the
ameliorative properties of L-DOPA (13). It is, therefore, par-
ticularly noteworthy that the VMAT2-deficient KA1 mice
showed qualitatively similar changes in striatal substance P and
enkephalin expression to the human disease, as well as to other
animal models of Parkinson’s disease that also result in re-
duced brain dopamine, such as the administration of the toxins
MPTP and 6-hydroxydopamine to monkeys (15) and rats (37),
respectively.
It is also clear that in several other ways the KA1 mice do
not model the typical features of Parkinson’s disease. There
was no evidence of dopamine cell loss in the substantia nigra,
and the mice, whilst being mildly akinetic, showed no signs of
resting tremor or rigidity. This may be due to the relatively
young age of the mice when tested (3 to 6 months), and we are
currently examining the possibility that larger motor deficits,
perhaps with concurrent loss of dopamine cells, will develop as
the animals age. Such findings would be consistent with the
usual history of idiopathic Parkinson’s disease, where age is a
major risk factor (31), and may also bear on recent speculation
about VMAT2 and its role in mediating efficient clearance of
dopamine in the selective vulnerability of nigral neurons in the
disease (35). Our VMAT2-deficient KA1 mice do indeed
model such a form of neuronal vulnerability, which manifests
itself as the emergence of frank pathology not only in old
animals but also in young animals subjected to additional toxic
insults such as MPTP. The titration of vulnerability thresholds
and the direct contribution made by VMAT2 functioning to
variation in the thresholds epitomize the potential value of our
mice in being able to examine, long term, the insidious dam-
aging consequences of abnormal intracellular handling of
monoamines. On the basis of our present findings, these mice
are likely to prove of immediate interest to models of Parkin-
son’s disease. They may also, however, be of use in probing
other aspects of monoaminergic function and dysfunction in
brain, the latter making important contributions to the study of
the pathogenesis of schizophrenia and addiction.
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